Odomos Oil (NN Diethylbenzamide 12% w/v) is oil-based medication used as a mosquito repellent in healthy infants.

“A single arm study to evaluate safety of Odomos Oil (NN Diethylbenzamide 12% w/v) mosquito repellent body oil in healthy infants - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2023/11/059772

Enrollment

Registered

2023-11-14

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Not Applicable: Not Applicable Intervention2: Odomos Oil: NN Diethylbenzamide 12% w/v up to 14 days Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Healthy Male or female infants aged 4-11 months

Exclusion criteria

Exclusion criteria: ? Aggravated history of allergies. ? Any Pre-existing diseased skin condition ? Conditions that, in the Investigator’s opinion, are contraindications for using NN Diethylbenzamide. ? Acute viral and bacterial infections at the moment of study inclusion or within 2 weeks before study inclusion; ? Participation in other clinical studies of experimental IP at the present time or within last 3 months before study inclusion; ? Parents lack of readiness to collaborate; ? Refuse to carefully adhere to Investigator’s prescriptions and indications according to the protocol.

Design outcomes

Primary

Measure	Time frame
To evaluate safety of NN Diethylbenzamide 12% w/v body oil in infants aged 4 to 11 monthsTimepoint: 14 days	—

Secondary

Measure	Time frame
1. Time to first allergic reaction, skin irritation, swelling, inflammation, rashes, redness at oil application site. 2. Global assessment by Investigator & parents ofTimepoint: 14 days	—

Countries

India

Contacts

Public ContactDr pooja Kondadi

Excel Hospital

poojakondadi318@gmail.com9440664042

Outcome results